Ph 2/3 trial of SIL204 planned in locally advanced pancreatic cancer in Q2 2026
Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “Results from the toxicology studies have cleared us to maintain our planned timelines to initiate SIL204’s Phase 2/3 clinical trial in pancreatic cancer. We have recently secured our CRO partner for the trial and continue to prepare regulatory submissions to both Israel’s Ministry of Health and Germany’s Health Authority (BfArM). SIL204’s preclinical package has shown remarkable potential as a cancer treatment, offering an innovative modality – stopping mutated, cancer-driving proteins before they are expressed. We are eager to prove this potential in the clinic and bring SIL204 to patients who could benefit from this treatment. We remain on track to initiate the first stage of SIL204’s advanced clinical development in the second quarter of 2026.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib